ADVFN Logo ADVFN

Não encontramos resultados para:
Verifique se escreveu corretamente ou tente ampliar sua busca.

Tendências Agora

Rankings

Parece que você não está logado.
Clique no botão abaixo para fazer login e ver seu histórico recente.

Hot Features

Registration Strip Icon for pro Negocie como um profissional: Aproveite discussões em tempo real e ideias que movimentam o mercado para superar a concorrência.

GNPX Genprex Inc

2,21
0,09 (4,25%)
27 Abr 2024 - Fechado
Atrasado em 15 minutos
Nome da Ação Código da Ação Bolsa de Valores Tipo de Ativo
Genprex Inc GNPX NASDAQ Ordinária
  Variação do Dia (p) Variação do Dia % Último Preço Hora
0,09 4,25% 2,21 01:00:05
Preço de Abertura Preço Mínimo Preço Máximo Fech. Hoje Fech. Anterior
2,17 2,09 2,3292 2,21 2,12
mais cotações »

Notícias Recentes

Data Hora Fonte Título
09/04/202409:31PRNUSGenprex Collaborators Report Positive Preclinical Data on..
03/04/202409:31PRNUSGenprex Expands Clinical Trial Sites for Acclaim-3 Clinical..
02/04/202409:31PRNUSGenprex Collaborators Publish Positive Preclinical Data with..
22/03/202417:10PRNUSGenprex Announces Closing of $6.5 Million Registered Direct..
19/03/202414:24PRNUSGenprex Announces $6.5 Million Registered Direct Offering..
19/03/202409:36PRNUSGenprex Announces $6.5 Million Registered Direct Offering..
12/03/202410:01PRNUSGenprex Receives Notice of Patent Grant for Korean Patent..
06/03/202410:30PRNUSGenprex Collaborators to Present Positive Preclinical Data..
07/02/202410:15PRNUSGenprex Expands Nonclinical Programs into New Therapeutic..
06/02/202409:30PRNUSGenprex to Present at Upcoming BIO CEO & Investor Conference
05/02/202409:30PRNUSGenprex Announces First Patient Dosed in Phase 2a Expansion..
31/01/202410:42PRNUSGenprex Announces 1-for-40 Reverse Stock Split Effective..
05/01/202409:00PRNUSGenprex Provides Business Update and Outlook for 2024
01/11/202308:30PRNUSGenprex to Present at BIO-Europe 2023 Conference
20/10/202308:30PRNUSGenprex to Host a Virtual Key Opinion Leader Event on..
04/10/202313:00PRNUSGenprex to Present Data on the Use of REQORSA® for the..
21/09/202309:30GLOBEGenprex Inc. (NASDAQ: GNPX) Receives Orphan Drug Designation..
20/09/202309:45IHNWPathways to Progress: How Orphan Drug Designation Sparks..
07/09/202308:30PRNUSGenprex to Present at Upcoming September Investor Conference
22/08/202308:30PRNUSGenprex Appoints Suzanne Thornton-Jones as Senior Vice..
10/08/202308:30PRNUSGenprex Granted FDA Orphan Drug Designation (ODD) for..
21/07/202317:15PRNUSGenprex Announces Closing of $7.5 Million Registered Direct..
19/07/202309:00PRNUSGenprex Announces $7.5 Million Registered Direct Offering..
18/07/202309:37PRNUSGenprex Signs Exclusive License to Additional Diabetes..
06/07/202309:17GLOBEIBN Announces Latest Episode of The Bell2Bell Podcast..
05/07/202309:35PRNUSGenprex Granted Chinese Patent for REQORSA® Immunogene..
28/06/202309:35PRNUSGenprex Receives U.S. FDA Fast Track Designation for..
30/05/202308:30PRNUSGenprex Receives Safety Review Committee Approval to Advance..
25/05/202318:00PRNUSGenprex Publishes Positive Clinical Data from Phase 1..
23/05/202308:30PRNUSGenprex Unveils New Video Featuring Chief Medical Officer..
08/05/202308:30PRNUSGenprex to Participate and Present at Upcoming May Industry..

Seu Histórico Recente

Delayed Upgrade Clock